Article thumbnail

Amyloidogenic Properties of a D/N Mutated 12 Amino Acid Fragment of the C-Terminal Domain of the Cholesteryl-Ester Transfer Protein (CETP)

By Victor García-González and Jaime Mas-Oliva

Abstract

The cholesteryl-ester transfer protein (CETP) facilitates the transfer of cholesterol esters and triglycerides between lipoproteins in plasma where the critical site for its function is situated in the C-terminal domain. Our group has previously shown that this domain presents conformational changes in a non-lipid environment when the mutation D470N is introduced. Using a series of peptides derived from this C-terminal domain, the present study shows that these changes favor the induction of a secondary β-structure as characterized by spectroscopic analysis and fluorescence techniques. From this type of secondary structure, the formation of peptide aggregates and fibrillar structures with amyloid characteristics induced cytotoxicity in microglial cells in culture. These supramolecular structures promote cell cytotoxicity through the formation of reactive oxygen species (ROS) and change the balance of a series of proteins that control the process of endocytosis, similar to that observed when β-amyloid fibrils are employed. Therefore, a fine balance between the highly dynamic secondary structure of the C-terminal domain of CETP, the net charge, and the physicochemical characteristics of the surrounding microenvironment define the type of secondary structure acquired. Changes in this balance might favor misfolding in this region, which would alter the lipid transfer capacity conducted by CETP, favoring its propensity to substitute its physiological function

Topics: Article
Publisher: Molecular Diversity Preservation International (MDPI)
OAI identifier: oai:pubmedcentral.nih.gov:3111648
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1998). Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis.
  2. (1999). Both oxidative stress-dependent and independent effects of amyloid beta protein are detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. Brain Res.
  3. (2003). Characterization of a naturally occurring new version of the cholesterol ester transfer protein (CETP) from small intestine.
  4. (2006). Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
  5. (2007). Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules.
  6. (2002). De novo designed peptide-based amyloid fibrils.
  7. (1995). Defective binding of neutral lipids by a carboxyl-terminal deletion mutant of cholesteryl ester transfer protein. Evidence for a carboxyl-terminal cholesteryl ester binding site essential for neutral lipid transfer activity.
  8. (2009). Disorder-to-order conformational transitions in protein structure and its relationship to disease.
  9. (2004). ENTH/ANTH proteins and clatrin-mediated membrane budding.
  10. (1999). Folding of amphipathic alpha-helices on membranes: energetics of helix formation by melittin.
  11. (2008). Forces between hydrophilic surfaces adsorbed with apolipoprotein AII alpha helices. Langmuir
  12. (2001). Frequencies of amino acid strings in globular protein sequences indicate suppression of blocks of consecutive hydrophobic residues. Protein Sci.
  13. (1998). Hydrophobic interactions of peptides with membrane interfaces.
  14. (2004). In search of new structural states of exchangeable apolipoproteins.
  15. (2006). Key molecule for microglial scavenger receptor function under oxidative stress.
  16. (2006). Kinetics and thermodynamics of amyloid fibril assembly.
  17. (2008). Lipid dependant disorder-to-order conformational transitions in apolipoprotein CI derived peptides.
  18. (2008). Mechanisms of microglia accumulation in Alzheimer’s disease: therapeutic implications.
  19. (2008). Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice.
  20. (2002). Natively unfolded proteins: A point where biology waits for physics. Protein Sci.
  21. (2000). Nature disfavors sequences of alternating polar and non-polar amino acids: implications for amyloidogenesis.
  22. (2003). Oxidative stress impairs endocytosis of the scavenger receptor class
  23. (1993). Point mutagenesis of carboxylterminal amino acids of cholesteryl ester transfer protein.
  24. (2007). Prevention of amyloid-like aggregation as a driving force of protein evolution. EMBO Rep.
  25. (2003). Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis.
  26. (2004). Protein flexibility and intrinsic disorder. Protein Sci.
  27. (2003). Protein folding and misfolding.
  28. (1999). Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay.
  29. (2007). Role of intermolecular forces in defining material properties of protein nanofibrils. Science
  30. (2001). Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science
  31. (1998). Stability of the C-terminal peptide of CETP mediated through an (i, i + 4) array.
  32. (2009). Structural Arrangement that Supports Lipid Transfer in the cholesteryl-ester transfer protein (CETP). USA-Mé xico Workshop in Biological Chemistry: Multidisciplinary Approaches to Protein Folding,
  33. (2005). Structure of the cross-beta spine of amyloid-like fibrils.
  34. (2002). Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases.
  35. (2009). Unfoldomics of human diseases: linking protein intrinsic disorder with diseases.